Literature DB >> 4208896

Evaluation of a new cephalosporin antibiotic, cephapirin.

P Wiesner, R MacGregor, D Bear, S Berman, K Holmes, M Turck.   

Abstract

Cephapirin sodium, a parenterally administered derivative of cephalosporanic acid, was tested in vitro against 150 stock cultures of Enterobacteriaceae and 30 stock cultures each of Pseudomonas aeruginosa and Staphylococcus aureus. Both broth- and agar-dilution techniques were employed with two sizes of inocula of organisms. At a concentration of 7.5 mug or less/ml, cephapirin inhibited and killed 100% of strains of Escherichia coli and Proteus mirabilis and more than 80% of Klebsiella species when tested against an inoculum of 10(5) bacterial cells/ml. However, even at 100 mug/ml, only a few isolates of other Enterobacteriaceae and Pseudomonas were inhibited. A 100-fold increase in the inoculum resulted in decreased susceptibility of organisms. All penicillin-susceptible as well as penicillin-resistant S. aureus isolates were inhibited and killed by 5 mug or less of cephapirin/ml when tested with an inoculum of either 10(4) or 10(6) organisms/ml. The drug also was studied in various doses in the treatment of 77 patients with diverse infections. Cephapirin was effective in the treatment of 27 of 32 patients with pulmonary infection, as well as in 6 of 7 patients with staphylococcal or streptococcal soft tissue infection. Of 25 patients with urinary-tract infections, 19 developed a negative culture during therapy. A single 4-g intramuscular dose of cephapirin was effective in only 2 of 11 patients with gonococcal urethritis or endocervicitis. Two patients with gonococcal urethritis treated with multiple injections were cured. The drug was well tolerated except for pain at the site of injection in 14 patients and phlebitis in 4 patients. No abnormalities in renal or hepatic function could be attributed to cephapirin. In addition, no abnormalities were found in the renal tubules of rabbits challenged with 500 mg of cephapirin/kg. If further studies document that cephapirin is well tolerated by the parenteral route, it may have advantages over cephalothin or cephaloridine.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4208896      PMCID: PMC444212          DOI: 10.1128/AAC.1.4.303

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  Factors determining the outcome of chemotherapy in infections of the urinary tract.

Authors:  R I LINDEMEYER; M TURCK; R G PETERSDORF
Journal:  Ann Intern Med       Date:  1963-02       Impact factor: 25.391

2.  Comparison of single-disc and tube-dilution techniques in determining antibiotic sensitivities of gram-negative pathogens.

Authors:  M TURCK; R I LINDEMEYER; R G PETERSDORF
Journal:  Ann Intern Med       Date:  1963-01       Impact factor: 25.391

3.  Nephrotoxicity due to cephaloridine: a light- and electron-microscopic study in rabbits.

Authors:  F Silverblatt; M Turck; R Bulger
Journal:  J Infect Dis       Date:  1970 Jul-Aug       Impact factor: 5.226

4.  Treatment of oral malignancies by radiotherapy.

Authors:  T Fichardt; A G Sandison
Journal:  J Dent Assoc S Afr       Date:  1968-09

5.  Laboratory studies with a new cephalosporanic acid derivative.

Authors:  D R Chisholm; F Leitner; M Misiek; G E Wright; K E Price
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1969

6.  In vitro and in vivo evaluation of cephalexin.

Authors:  H Clark; M Turck
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1968

7.  New cephalosporin antibiotic--cephaloridine. Clinical and laboratory evaluation.

Authors:  M Turck; D W Belcher; A Ronald; R H Smith; J F Wallace
Journal:  Arch Intern Med       Date:  1967-01

8.  A critical evaluation of nalidixic acid in urinary-tract infections.

Authors:  A R Ronald; M Turck; R G Petersdorf
Journal:  N Engl J Med       Date:  1966-11-17       Impact factor: 91.245

9.  Laboratory and pharmacologic studies of BL-P-1322 (cephapirin sodium) in children.

Authors:  R C Gordon; F F Barrett; D J Clark; M D Yow
Journal:  Curr Ther Res Clin Exp       Date:  1971-06

10.  Factors influencing in vitro susceptibility to the cephalosporins and clinical trial of an oral cephalosporin, cephaloglycin.

Authors:  A R Ronald; M Turck
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1966
View more
  7 in total

1.  Hemodialysis-associated infections: treatment with cephapirin.

Authors:  S J Berman; W H Boughton; J G Sugihara; E G Wong; A W Siemsen
Journal:  Antimicrob Agents Chemother       Date:  1978-01       Impact factor: 5.191

2.  Treatment of pneumonia and other serious bacterial infections with cephapirin.

Authors:  H G Robson; M I Bowmer
Journal:  Antimicrob Agents Chemother       Date:  1974-09       Impact factor: 5.191

3.  Comparative serum levels and protective activity of parenterally administered cephalosporins in experimental animals.

Authors:  L R Fare; P Actor; C Sachs; L Phillips; M Joloza; J F Pauls; J A Weisbach
Journal:  Antimicrob Agents Chemother       Date:  1974-08       Impact factor: 5.191

4.  Activity of four cephalosporin antibiotics in vitro against bovine udder pathogens and pathogenic bacteria isolated from newborn calves.

Authors:  G Ziv
Journal:  Antimicrob Agents Chemother       Date:  1976-03       Impact factor: 5.191

5.  Double-blind controlled comparison of phlebitis produced by cephapirin and cephalothin.

Authors:  J Carrizosa; M E Levison; D Kaye
Journal:  Antimicrob Agents Chemother       Date:  1973-02       Impact factor: 5.191

Review 6.  The cephalosporins: activity and clinical use.

Authors:  A J Weinstein
Journal:  Drugs       Date:  1980-08       Impact factor: 9.546

7.  Development and validation of a UPLC-MS/MS method to monitor cephapirin excretion in dairy cows following intramammary infusion.

Authors:  Partha Ray; Katharine F Knowlton; Chao Shang; Kang Xia
Journal:  PLoS One       Date:  2014-11-06       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.